iMTA developed novel ways to identify health outcomes suitable for economic evaluations (‘utilities’).
Key achievements in the field of Multiple Sclerosis
iMTA performed a costing study for intrathecal baclofen therapy against spasms, also occurring in multiple sclerosis. The pump was fitted in a home based situation to avoid that patients have to return to the hospital.
iMTA developed the condition specific MSIS-PBM, a preference based instrument based on the Multiple Sclerosis Impact Scale 29. Using the Time Trade-off method in about 400 group interviews in The Netherlands, a selection of items (selected using Rasch-analysis and expert opinion) of the MSIS-29 was weighted. The resulting instrument is more sensitive than EQ5D for minor impairments and better discriminates between patients with EDSS score 3,4 and 5 than EQ5D. Utilities can be calculated from the MSIS-29 directly.